Myanmar FDA: The Regulatory Authority for Medical Devices

1. Key takeaways

The competent authority for medical devices in Myanmar is the Department of Food and Drug Administration (FDA) of Myanmar, which is under the Ministry of Health (historically also expressed as the Ministry of Health and Sports, MoHS). The department oversees pharmaceuticals, medical devices and food hygiene, and issues three types of core documents: the Import Recommendation, the Import Notification and the Manufacturing License.

• Myanmar FDA is a single-window authority: registration submission, technical review, import control and post-market surveillance are all handled by the same agency, with no internal check-and-balance buffer between health departments.
• This feature simplifies communication, but it also means there is no intermediate remedy step between the review opinion and the market access decision.
• The agency was established in 1995; its governing board, the Myanmar Food and Drug Board of Authority, was created under the National Drug Law (Law No. 7 of 1992).
• It oversees 3 categories of business and issues 3 types of core documents.
• The procedural rules actually applied to dossiers are carried by the Technical Guideline for Online Submission of Medical Devices and the FDA e-Submission portal.
• The enforcement basis is section 3(3)(d) of the Public Health Law 1972, which operates as a residual authority in the absence of a dedicated device statute, so the FDA can take action against non-compliant products without waiting for device-specific rules.

2. Legal basis

The institutional and legal coordinates of the Myanmar FDA are set out below. Because the department was created under drug legislation, its documentary toolkit carries the marks of pharmaceutical control, and applicants should read the instruments together rather than treating them as isolated rules.

3. Expert insights

Insight 1: the historical origin of the authority determines the pharmaceutical colouring of its powers. The FDA was established under the National Drug Law, and its institutional DNA comes from drug regulation. This explains why Myanmar’s device rules borrow extensively from the pharmaceutical toolkit: import recommendation, import notification and manufacturing licences all bear the traces of drug control. Companies preparing dossiers should expect the authority to scrutinise device documentation with the rigour of pharmaceutical review.

Insight 2: the Import Recommendation and the Import Notification are two parallel documents and must not be conflated. The former is a recommendation document for the import stage, while the latter is a registration-type document. When planning customs clearance paperwork, companies must confirm which of the two their product requires, or whether both are needed. This determination should be made upfront at the registration stage, not on the eve of shipment.

Insight 3: the single-window structure lowers communication costs but compresses the space for correction. All applications, changes, renewals and deficiency responses are processed by the same agency. Companies must therefore secure first-submission quality, because there is no interdepartmental re-check to fall back on.

Insight 4: the public naming of the institution shows historical variation. Public materials contain both the Ministry of Health and Sports and the Ministry of Health. This article consistently refers to the Food and Drug Administration under the Ministry of Health of Myanmar; the exact official designation should follow the latest official announcements. This is a practical estimate pending verification against the most recent publication.

Insight 5: the technical guideline is the practical carrier of the procedural rules. The Technical Guideline for Online Submission of Medical Devices specifies definitions, classification, labelling, grouping, the authorised letter format, product safety declaration, declaration of conformity and the mandatory problem reporting form, and it is the direct basis for preparing the dossier. Because this guideline defines the grouping rules and the required declarations, deviations from its formats are among the most common causes of deficiency letters, and each such deficiency extends the review timeline measurably.

4. Practical recommendations

• Concentrate all regulatory communication on the Myanmar FDA single window. Maintain a unified correspondence register to avoid inconsistent interpretations caused by contacting multiple channels.
• Prepare document formats strictly against the technical guideline. The authorised letter, declaration of conformity, product safety declaration and similar texts must follow the formats prescribed in the guideline.
• Determine the required certificate type upfront. At the registration stage, confirm whether the product falls under an exempted list or requires an Import Recommendation or Import Notification.
• Raise the quality of the first submission. Because there is no interdepartmental re-check buffer, the completeness of the first submission directly determines the review timeline.
• Track the latest announcements on the agency’s name and functions. Follow the most recent official publication and update internal documents accordingly.

5. Verification checklist

• □ Confirmed that the competent authority is the Myanmar Department of Food and Drug Administration (FDA) under the Ministry of Health
• □ Confirmed that the FDA was founded in 1995 and that its board was established under Law No. 7 of 1992
• □ Confirmed that the scope of business covers pharmaceuticals, medical devices and food hygiene
• □ Confirmed that the documents issued include the Import Recommendation, the Import Notification and the Manufacturing License
• □ Established a unified correspondence register for the FDA single window
• □ Obtained the current version of the Technical Guideline for Online Submission of Medical Devices
• □ Confirmed the required certificate type at the registration stage

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com